Gene therapy (AAV vector) · Gene replacement · developed by UniQure Biopharma B.V.
AMT-191 is an adeno-associated virus serotype 5 based vector carrying a DNA sequence for human alpha-galactosidase A (GLA). Given intravenously, it is intended to drive liver expression of the lysosomal enzyme GLA in plasma, and is being studied in Fabry disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06270316 | Phase 1/2 | Fabry Disease | Recruiting | QURE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fabry Disease
Updated Oct 25, 2026. Something wrong or missing? Report it on the QURE page.
See QURE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
QURE catalysts and pipeline →